Showing 1 to 3 of 3 results


Pfizer to Acquire Metsera for $7.3 Billion
Pfizer is close to acquiring the weight-loss drug startup Metsera for $7.3 billion, marking Pfizer's first major acquisition in two years and a significant entry into the lucrative weight-loss drug market.
Pfizer to Acquire Metsera for $7.3 Billion
Pfizer is close to acquiring the weight-loss drug startup Metsera for $7.3 billion, marking Pfizer's first major acquisition in two years and a significant entry into the lucrative weight-loss drug market.
Progress
32% Bias Score


Pfizer Acquires Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer, the US pharmaceutical giant, has acquired the biopharmaceutical company Metsera for $4.9 billion to enter the obesity drug market, gaining access to Metsera's pipeline of obesity and cardiometabolic therapies.
Pfizer Acquires Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer, the US pharmaceutical giant, has acquired the biopharmaceutical company Metsera for $4.9 billion to enter the obesity drug market, gaining access to Metsera's pipeline of obesity and cardiometabolic therapies.
Progress
40% Bias Score

Pfizer to Acquire Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer announced a $4.9 billion cash acquisition of Metsera, a biopharmaceutical firm with a pipeline of obesity and cardiometabolic disease treatments, to expand into the growing obesity drug market.

Pfizer to Acquire Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer announced a $4.9 billion cash acquisition of Metsera, a biopharmaceutical firm with a pipeline of obesity and cardiometabolic disease treatments, to expand into the growing obesity drug market.
Progress
44% Bias Score
Showing 1 to 3 of 3 results